A commercial court in Noida has affirmed the injunction/restraint in favor of Jubilant against entities involved in the manufacture and supply of certain pharmaceutical products viz. Losartan, Citalopram, and Amlodipine, using, without authorisation, proprietary technology, confidential trade secrets, and original copyright product dossiers of Jubilant.
The injunction order was passed against Medreich Limited, V S International Private Limited, Gracure Pharmaceuticals Limited, and Jamp India Pharmaceuticals Private Limited, a subsidiary of Jamp Pharma Corporation, Canada, which were either directly manufacturing and supply/exporting to JAMP Canada these pharmaceutical products, or facilitating such illegal activities.
The court recognised that Jubilant has a prima facie case to protect its literary work against use without knowledge in India, finding that the balance of convenience lies in favor of the plaintiff and that plaintiff has also suffered irreparable loss and injury.
Medreich, V S International, Gracure, and Jamp India made multiple attempts to get the stay vacated and sell/export more products to Jamp Canada.
The petitioner was represented by Vaibhav Mittal and Vashistha Parashar, Defendants were represented by Arjun Krishnan.
